Literature DB >> 19755419

Proteolytic cleavage of type I collagen generates an autoantigen in autoimmune uveitis.

Purushottam Jha1, Balasubramanian Manickam, Bharati Matta, Puran S Bora, Nalini S Bora.   

Abstract

This study was initiated to induce experimental autoimmune anterior uveitis (EAAU) in Lewis rats by melanin-associated antigen (MAA; 22-kDa fragment of type I collagen alpha2 chain) derived from rat iris and ciliary body (CB), to localize MAA within the eye, and to investigate the possible mechanism of MAA generation in vivo. The EAAU model replicates idiopathic human anterior uveitis. Lewis rats sensitized to rat MAA developed anterior uveitis, and EAAU induced by rat MAA can be adoptively transferred to naive syngenic rats by MAA-primed T cells. Animals immunized with rat MAA developed cellular immunity to the antigen. MAA was detected only in the iris and CB of the eye. Iris and CB were the major source of matrix metalloproteinase-1 (MMP-1) in the naive eye, and ocular expression of MMP-1 was up-regulated, whereas expression of tissue inhibitor of metalloproteinase 1 decreased before the onset of EAAU. These results demonstrated that EAAU can be induced by autologous MAA. Uveitogenic antigen is present only in the iris and CB of the eye, and the imbalance between MMP-1 and tissue inhibitor of metalloproteinase 1 may play a role in the generation of MAA in vivo. Collectively, the evidence presented here suggests that MAA is an autoantigen in EAAU. These observations may extend to idiopathic human anterior uveitis and facilitate the development of antigen-specific therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755419      PMCID: PMC2781536          DOI: 10.1074/jbc.M109.033381

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases.

Authors:  J Ottl; D Gabriel; G Murphy; V Knäuper; Y Tominaga; H Nagase; M Kröger; H Tschesche; W Bode; L Moroder
Journal:  Chem Biol       Date:  2000-02

Review 2.  Autoimmune diseases.

Authors:  A Davidson; B Diamond
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

3.  Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells.

Authors:  Bharati Matta; Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

4.  The complement system plays a critical role in the development of experimental autoimmune anterior uveitis.

Authors:  Purushottam Jha; Jeong-Hyeon Sohn; Qin Xu; Hiroki Nishihori; Yali Wang; Saori Nishihori; Balasubramanian Manickam; Henry J Kaplan; Puran S Bora; Nalini S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

5.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

Review 6.  Intraocular diseases - anterior uveitis.

Authors:  Nalini S Bora; Henry J Kaplan
Journal:  Chem Immunol Allergy       Date:  2007

7.  Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis.

Authors:  Philippe E Van den Steen; Paul Proost; Bernard Grillet; David D Brand; Andrew H Kang; Jo Van Damme; Ghislain Opdenakker
Journal:  FASEB J       Date:  2002-03       Impact factor: 5.191

8.  Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method.

Authors:  Takeo Higashikata; Masakazu Yamagishi; Toshio Higashi; Izumi Nagata; Koji Iihara; Susumu Miyamoto; Hatsue Ishibashi-Ueda; Noritoshi Nagaya; Takashi Iwase; Hitonobu Tomoike; Aiji Sakamoto
Journal:  Atherosclerosis       Date:  2005-07-21       Impact factor: 5.162

9.  Crucial role of apoptosis in the resolution of experimental autoimmune anterior uveitis.

Authors:  Purushottam Jha; Bharati Matta; Valeriy Lyzogubov; Ruslana Tytarenko; Puran S Bora; Nalini S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

Review 10.  Molecular mechanisms of autoimmunity.

Authors:  M Zouhair Atassi; Paolo Casali
Journal:  Autoimmunity       Date:  2008-03       Impact factor: 2.815

View more
  5 in total

Review 1.  [Pharmacological treatment strategies and surgical options for uveitis].

Authors:  Justus G Garweg
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

2.  Imbalance Between Th17 Cells and Regulatory T Cells During Monophasic Experimental Autoimmune Uveitis.

Authors:  Lian Zhang; Fangzhu Wan; Jike Song; Kai Tang; Fengming Zheng; Junguo Guo; Dadong Guo; Hongsheng Bi
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

3.  Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU).

Authors:  Balasubramanian Manickam; Purushottam Jha; Natalie J Hepburn; B Paul Morgan; Claire L Harris; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2010-09-16       Impact factor: 4.407

4.  Inhibition of complement alternative pathway suppresses experimental autoimmune anterior uveitis by modulating T cell responses.

Authors:  Balasubramanian Manickam; Purushottam Jha; Bharati Matta; Juan Liu; Puran S Bora; Nalini S Bora
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

5.  Proteolysis breaks tolerance toward intact α345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for α345NC1 hexamers.

Authors:  Florina Olaru; Xu-Ping Wang; Wentian Luo; Linna Ge; Jeffrey H Miner; Sandra Kleinau; Xochiquetzal J Geiger; Andrew Wasiluk; Laurence Heidet; A Richard Kitching; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.